Effects of carry-over of fluoroquinolones on the susceptibility of commensal Escherichia coli in the intestinal microbiota of poultry;Einfluss von fluorchinolonen auf die resistenzentwicklung kommensaler escherichia coli im darm beim huhn

Berliner und Munchener Tierarztliche Wochenschrift

Volumn 127, Issue 11-12, 2014, Pages 478-485

  Scherz, Gesine ^a   Stahl, Jessica ^a   Glünder, Gerhard ^a   Kietzmann, Manfred ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Antimicrobial resistance; Carry over; E. coli; Fluoroquinolones

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

ANTIINFECTIVE AGENT; ENROFLOXACIN; QUINOLONE DERIVATIVE;

ANIMAL; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ESCHERICHIA COLI; FEMALE; INTESTINE; MICROBIAL CONSORTIUM; MICROBIOLOGY; POULTRY DISEASES;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FEMALE; FLUOROQUINOLONES; INTESTINES; MICROBIAL CONSORTIA; POULTRY DISEASES;

EID: 84926367359     PISSN: 00059366     EISSN: None     Source Type: Journal    
DOI: 10.2376/0005-9366-127-478     Document Type: Article

References (47)

1. Anadon A, Martinez-Larranaga MR, Diaz MJ, Bringas P, Martinez MA, Fernandez-Cruz ML, Fernandez MC, Fernandez R (1995): Pharmacokinetics and residues of enrofloxacin in chickens. Am J Vet Res 56: 501-506.
2. Andersson MI, MacGowan AP (2003): Development of the quinolones. J Antimicrob Chemother 51 Suppl 1: 1-11.
3. Bagel S, Hullen V, Wiedemann B, Heisig P (1999): Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother 43: 868-875.
4. Bauditz R (1987): Results of clinical studies with Baytril in poultry. Vet Med Rev 2: 130-136.
5. Belland RJ, Morrison SG, Ison C, Huang WM (1994): Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol 14: 371-380.
6. Blondeau JM (2004): Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 49 Suppl 2: S73-78.
7. Blondeau JM (2009): New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet Dermatol 20: 383-396.
8. Cirz RT, Chin JK, Andes DR, de Crecy-Lagard V, Craig WA, Romesberg FE (2005): Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol 3: e176.
9. CLSI (2008): Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard. CLSI document M31-A3, 3rd edition.
10. Dong Y, Zhao X, Domagala J, Drlica K (1999): Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 43: 1756-1758.
11. Drlica K (2003): The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17.
12. Drlica K, Zhao X (1997): DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61: 377-392.
13. Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X (2009): Quinolones: action and resistance updated. Curr Top Med Chem 9: 981-998.
14. Elliot CT, McCaughey WJ, Crooks SRH, McEvoy JDG (1994): Effect of short term exposure of unmedicated pigs to sulphadimidine contaminated housing. Vet Rec 134: 450-451.
15. EUCAST (2013a): Enrofloxacin/Escherichia coli EUCAST MIC Distribution. http://mic.eucast.org/Eucast2/regShow.jsp?Id=9596.
16. EUCAST (2013b): EUCAST definitions of clinical breakpoints and epidemiological cut-off values. http://www.srga.org/Eucastwt/ eucastdefinitions.htm.
17. Everett MJ, Jin YF, Ricci V, Piddock LJ (1996): Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 40: 2380-2386.
18. Ewers C, Bethe A, Semmler T, Guenther S, Wieler LH (2012): Extended-spectrum beta-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. Clin Microbiol Infect 18: 646-655.
19. Gillespie SH, Voelker LL, Ambler JE, Traini C, Dickens A (2003): Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb Drug Resist 9: 17-24.
20. Gross CH, Parsons JD, Grossman TH, Charifson PS, Bellon S, Jernee J, Dwyer M, Chambers SP, Markland W, Botfield M, Raybuck SA (2003): Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance. Antimicrob Agents Chemother 47: 1037-1046.
21. Gullberg E, Cao S, Berg OG, Ilback C, Sandegren L, Hughes D, Andersson DI (2011): Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog 7: e1002158.
22. Hamscher G, Pawelzick HT, Höper H, Nau H (2003): Antibiotics in dust originating from a pig-fattening farm: a new source of health hazard for farmers? Environ Health Persp 111: 1590-1594.
23. Hooper DC (2001): Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32 Suppl 1: S9-S15.
24. Hooper DC (2002): Fluoroquinolone resistance among Grampositive cocci. Lancet Infect Dis 2: 530-538.
25. Howard BM, Pinney RJ, Smith JT (1993): Function of the SOS process in repair of DNA damage induced by modern 4-quinolones. J Pharm Pharmacol 45: 658-662.
26. Intorre L, Vanni M, Di Bello D, Pretti C, Meucci V, Tognetti R, Soldani G, Cardini G, Jousson O (2007): Antimicrobial susceptibility and mechanism of resistance to fluoroquinolones in Staphylococcus intermedius and Staphylococcus schleiferi. J Vet Pharmacol Ther 30: 464-469.
27. Janusch F (2014): Entwicklung, Validierung und Anwendung spurenanalytischer Methoden zum Nachweis von Fluorchinolon- Antibiotika in biologischen Matrices mittels LC-MS/MS. Gie.en, Justus-Liebig University, Diss.
28. Kamphues J (1996): Risiken bei der Medikierung von Futter und Wasser in Tierbestanden. Dtsch Tierarztl Wochenschr 103: 250-256.
29. Kietzmann M, Markus W, Chavez J, Bollwahn W (1995): [Drug residues in untreated swine]. Dtsch Tierarztl Wochenschr 102: 441-442.
30. Knoll U, Glunder G, Kietzmann M (1999): Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. J Vet Pharmacol Ther 22: 239-246.
31. Kogelheide B (2007): Broiler and turkey drinking systems - A study of oxytetracycline carry-over. Hannover, University of Veterinary Medicine Hannover, Foundation.
32. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Moller N, Hughes D (2005): Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 49: 2343-2351.
33. Lim S, Bast D, McGeer A, de Azavedo J, Low DE (2003): Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 9: 833-837.
34. Looft T, Johnson TA, Allen HK, Bayles DO, Alt DP, Stedtfeld RD, Sul EJ, Stedtfeld TM, Chai B, Cole JR, Hashsham SA, Tiedje JM, Stanton TB (2012): In-feed antibiotic affects on the swine intestinal microbiome. PNAS 109: 1191-1196.
35. Miranda JM, Vazquez BI, Fente CA, Barros-Velazquez J, Cepeda A, Franco CM (2008): Evolution of resistance in poultry intestinal Escherichia coli during three commonly used antimicrobial therapeutic treatments in poultry. Poult Sci 87: 1643-1648.
36. Moore AM, Patel S, Forsberg KJ, Wang B, Bentley G, Razia Y, Qin X, Tarr PI, Dantas G (2013): Pediatric fecal microbiota harbor diverse and novel antibiotic resistance genes. PLoS One 8: e78822.
37. Pan XS, Ambler J, Mehtar S, Fisher LM (1996): Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 40: 2321-2326.
38. Pletz MW, Shergill AP, McGee L, Beall B, Whitney CG, Klugman KP (2006): Prevalence of first-step mutants among levofloxacinsusceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 50: 1561-1563.
39. Schaberle TF, Hack IM (2014): Overcoming the current deadlock in antibiotic research. Trends Microbiol 22: 165-167.
40. Scherz G (2013): Carryover of subtherapeutic antimicrobial dosages of enrofloxacin and the influence on the development of antibiotic resistance of commensal Escherichia coli in the intestine of poultry. Hannover, University of Veterinary Medicine Hannover, Foundation, Diss.
41. Schuurmans JM, Koenders BB, ter Kuile BH, Hayali AS (2010): Rapid induction of resistance to the fluoroquinolone enrofloxacin in Pseudomonas putida NCTC 10936. Int J Antimicrob Agents 35: 612-613.
42. Tyczkowska K, Hedeen KM, Aucoin DP, Aronson AL (1989): High-performance liquid chromatographic method for the simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in canine serum and prostatic tissue. J Chromatogr 493: 337-346.
43. Van der Horst MA, Fabri TH, Schuurmans JM, Koenders BB, Brul S, ter Kuile BH (2013): Effects of therapeutical and reduced levels of antibiotics on the fraction of antibiotic-resistant strains of Escherichia coli in the chicken gut. Foodborne Pathog Dis 10(1): 55-61.
44. Weigel LM, Steward CD, Tenover FC (1998): gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 42: 2661- 2667.
45. Wu Y, Wang Z, Liao X, Chen Z (2005): Study on the Excretion of Enrofloxacin in Chicken and Its Degradation in Chicken Feces. Acta Vet Zootech Sinica 36: 1069-1074.
46. Zessel K (2012): Decreased entry of veterinary drug residues into the environment by improved degradability of sulphonamides. Hannover, University of Veterinary Medicine Hannover, Foundation, Diss.
47. Zhou J, Dong Y, Zhao X, Lee S, Amin A, Ramaswamy S, Domagala J, Musser JM, Drlica K (2000): Selection of antibiotic- resistant bacterial mutants: allelic diversity among fluoroquinolone- resistant mutations. J Infect Dis 182: 517-525.